Authors
Latest:
Expert Commentary on the Product Profile of Amivantamab-vmjwIn an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.
Latest:
Unmet Needs and Future Perspectives on Treating Patients With Multiple MyelomaConcluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.
Latest:
Managing Risks, Planning Treatment, & Making Progress in Pancreatic CancerA nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.
Latest:
Advanced Penile Cancer Presenting With Renal Failure“MK,” a man aged 67 years, presented with fatigue and nausea to his primary care physician. CT staging scans confirmed the primary tumor and a suspicious left 1.2-cm inguinal lymph node but no distant metastases. MRI of the pelvis revealed complete replacement of the penis with tumor as well as invasion into the scrotum and bilateral groin soft tissue; additionally, early pubic bone invasion was present, with left groin lymphadenopathy. Biopsy verified squamous cell carcinoma of the penis, and discussion with the multidisciplinary team uroradiologist confirmed bony invasion.
Latest:
Best Treatment Selection in Clear-Cell RCCMedical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Latest:
Optimizing Therapy in Frontline Multiple Myeloma Not Eligible for TransplantExperts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.
Latest:
Tony S. Mok, MD, Reviews Importance of Adjuvant Nivolumab in Resectable NSCLCTony S. Mok, MD, spoke about utilizing adjuvant or neoadjuvant treatment for patients with non–small cell lung cancer.
Latest:
Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and OncologyConflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
Latest:
Navigating Newer Treatment Regimens in Melanoma: Practical Approaches to Dosing and Adverse Event ManagementPanelists discuss how community oncologists have developed good experience managing immune-related adverse events and are increasingly adopting relatlimab-nivolumab due to its lower toxicity profile and convenient administration schedule of half-hour infusions every four weeks.
Latest:
Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and CancerHuman saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.
Latest:
Future Perspectives and Unmet Needs in CLLThe panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.
Latest:
Improving the RCC Patient Journey and Future Therapeutic DirectionsPanelists discuss areas for improvement in the RCC journey from the patient perspective, including the impact of emerging research on their experience, and explore therapeutic approaches and clinical research areas that show promise for improving outcomes in advanced RCC, with a focus on novel targets and mechanisms of action in development.
